159017-37-5

Basic information

• Product Name: (E)-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]cinnamaldehyde
• Synonyms: (E)-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]cinnamaldehyde
• CAS NO: 159017-37-5
• Molecular Weight: 333.387
• Mol File: 159017-37-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (E)-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]cinnamaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]cinnamaldehyde(159017-37-5)
• EPA Substance Registry System: (E)-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]cinnamaldehyde(159017-37-5)

Safety Data

• Hazardous Substances Data: 159017-37-5(Hazardous Substances Data)

Upstream product

• 159017-51-3 methyl 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]cinnamate 
• 178238-70-5 (E)-3-{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-acrylic acid ethyl ester 
• 103788-59-6 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzaldehyde 
• 159017-30-8 (E)-3-{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-prop-2-en-1-ol 

Downstream Products

• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 1026936-75-3 ethyl (E)-5-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-2,4-pentadienoate 

Relevant articles and documents

Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities

Two novel classes of 2,4-thiazolidinediones and 2,4-oxazolidinediones with an ω-(azolylalkoxyphenyl)alkyl substituent at the 5-position were prepared and their antidiabetic effects were evaluated in two genetically obese and diabetic animal models, KKAy mice and Wistar fatty rats. A large number of the 2,4-thia(oxa)zolidinediones showed potent glucose- and lipid-lowering activities. The antidiabetic activities of the 2,4-oxazolidinediones were superior to those of the 2,4-thiazolidinediones. Among the compounds, both enantiomers of 5-[3-[4-[2-(2-furyl)-5-methyl-4-oxazolylmethoxy]-3- methoxyphenyl]propyl]-2,4-oxazolidinedione (64), one of the most interesting compounds in terms of activity, were synthesized by using an asymmetric O-acetylation of the corresponding α-hydroxyvalerate (26) with immobilized lipase, followed by cyclization of the oxazolidinedione ring. (R)-(+)-64 showed more potent glucose-lowering activity (effective dose (ED)25 = 0.561 mg/kg/d) than (S)-(-)-64 (ED25 > 1.5 mg/kg/d) or pioglitazone (ED25 = 6 mg/kg/d) in KKAy mice. It also exhibited a 10-fold more potent antidiabetic activity (ED25 = 0.05 mg/kg/d) than pioglitazone (ED25 = 0.5 mg/kg/d) in Wistar fatty rats. The antidiabetic effects of this compound are considered to be due to its potent agonistic activity for peroxisome proliferator-activated receptor γ (EC50 = 8.87 nM).